LONDON--(BUSINESS WIRE)--Oct 25, 2018--According to the market research report released by Technavio, the global head and neck cancer treatment market is expected to accelerate at a CAGR of more than 8% during the forecast period. The rising incidence of head and neck cancer is one of the key factors triggering the growth of the market.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20181025005793/en/

According to the market research report released by Technavio, the global head and neck cancer treatment market is expected to accelerate at a CAGR of over 8% until 2021. (Graphic: Business Wire)

This research report titled ‘ ’ provides an in-depth analysis of the market in terms of revenue and emerging market trends. It also includes an up-to-date analysis and forecasts for various market segments and all geographical regions.

This report is available at a USD 1,000 discount for a limited time only:

The market research analysis categorizes the global head and neck cancer treatment market into the following types of cancer:

Oral cavity cancerLaryngeal cancerPharyngeal cancer

In 2016, the oral cavity cancer segment accounted for 47% share of the global market. Oral cavity cancer is the most common type of head and neck cancer and is commonly seen in the tongue, lips, floor of the mouth, cheeks, and hard palate.

Global head and neck cancer treatment market: Top emerging trend

Increased combination therapy is an emerging trend in this market space. Drugs used in chemotherapy, such as carboplatin and gemcitabine, work in different ways to stop the growth of cancer cells. These drugs either kill the cells or stops the cell division. Giving combination chemotherapy along with laboratory-treated T lymphocytes may kill a greater number of tumor cells. Most researches in the industry are focused to provide combination therapies that would further improve the effectiveness of the treatment and the quality of the patient's life. Chemotherapy drugs give the optimal results when given in combination, this is known as combination chemotherapy. For any cancer, the best approach is the combination of radiation, surgery, and chemotherapy. Sometimes chemotherapy or radiation therapy is given before surgery to shrink the tumor, which further improves the chances of complete surgical removal.

Looking for more information on this market?

Technavio’s sample reports are free of charge and contain multiple sections of the report including the market size and forecast, drivers, challenges, trends, and more.

Technavio’s report provides expert market research on the following topics:

Executive Report

Market OutlineGlobal Head and Neck Cancer Treatment Market Overview

Market Insights

Market Sizing and ForecastsMarket GrowthMarket Drivers and ChallengesKey Emerging Trends

Market Segmentation Analysis

Regional comparison (APAC, Americas, and EMEA)Key leading countriesMarket segmentation by cancer type (oral cavity cancer, laryngeal cancer, and pharyngeal cancer)

Vendor Landscape

Vendor classificationMarket positioning of vendorsCompetitive scenarioAnalysis of top vendors (Bristol-Myers Squibb, Eli Lilly, Merck, and Pfizer)

About Technavio

is a leading global technology research and advisory company. Their research and analysis focuses on emerging market trends and provides actionable insights to help businesses identify market opportunities and develop effective strategies to optimize their market positions.

With over 500 specialized analysts, Technavio’s report library consists of more than 10,000 reports and counting, covering 800 technologies, spanning across 50 countries. Their client base consists of enterprises of all sizes, including more than 100 Fortune 500 companies. This growing client base relies on Technavio’s comprehensive coverage, extensive research, and actionable market insights to identify opportunities in existing and potential markets and assess their competitive positions within changing market scenarios.

If you are interested in more information, please contact our media team at .

View source version on businesswire.com:https://www.businesswire.com/news/home/20181025005793/en/

CONTACT: Technavio Research

Jesse Maida

Media & Marketing Executive

US: +1 844 364 1100

UK: +44 203 893 3200

www.technavio.com

KEYWORD:

INDUSTRY KEYWORD: HEALTH ONCOLOGY

SOURCE: Technavio Research

Copyright Business Wire 2018.

PUB: 10/25/2018 12:54 PM/DISC: 10/25/2018 12:54 PM

http://www.businesswire.com/news/home/20181025005793/en

Copyright Business Wire 2018.

(0) comments

Welcome to the discussion.

Keep it Clean. Please avoid obscene, vulgar, lewd, racist or sexually-oriented language.
PLEASE TURN OFF YOUR CAPS LOCK.
Don't Threaten. Threats of harming another person will not be tolerated.
Be Truthful. Don't knowingly lie about anyone or anything.
Be Nice. No racism, sexism or any sort of -ism that is degrading to another person.
Be Proactive. Use the 'Report' link on each comment to let us know of abusive posts.
Share with Us. We'd love to hear eyewitness accounts, the history behind an article.

Thank you for Reading!

Please log in, or sign up for a new account and purchase a subscription to read or post comments.